EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis

Sebastian Foersch, Maxime Schmitt, Anne-Sophie Litmeyer, Markus Tschurtschenthaler iD, Thomas Gress, Detlef K Bartsch, Nicole Pfarr, Katja Steiger iD, Carsten Denkert, Moritz Jesinghaus iD

The Journal of Pathology: Clinical Research · 2024-09 · 10 (5)

DOI: 10.1002/2056-4538.12394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 23.08.2024. Verfasst von Sebastian Foersch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University Medical Center, Mainz, Germany. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antigens, Neoplasm, Cell Adhesion Molecules, Phenotype. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) directed to trophoblast cell surface antigen 2 (TROP2) have gained approval as a therapeutic option for advanced triple‐negative breast cancer, and TROP2 expression has been linked to unfavourable outcomes in various malignancies. In colorectal carcinoma (CRC), there is still a lack of comprehensive studies on its expression frequency and its prognostic implications in relation to the main clinicopathological parameters. We examined the expression of TROP2 in a large cohort of 1,052 CRC cases and correlated our findings with histopathological and molecular parameters, tumour stage, and patient outcomes. TROP2 was heterogeneously expressed in 214/1,052 CRCs (20.3%), with only a fraction of strongly positive tumours. TROP2 expression significantly correlated with an invasive histological phenotype (e.g. increased tumour budding/aggressive histopathological subtypes), advanced tumour stage, microsatellite stable tumours, and p53 alterations. While TROP2 expression was prognostic in univariable analyses of the overall cohort (e.g. for disease‐free survival, p < 0.001), it exhibited distinct variations among important clinicopathological subgroups (e.g. right‐ versus left‐sided CRC, microsatellite stable versus unstable CRC, Union for International Cancer Control [UICC] stages) and lost its significance in multivariable analyses that included stage and CRC histopathology. In summary, TROP2 is quite frequently expressed in CRC and associated with an aggressive histopathological phenotype and microsatellite stable tumours. Future clinical trials investigating anti‐TROP2 ADCs should acknowledge the observed intratumoural heterogeneity, given that only a subset of TROP2‐expressing CRC show strong positivity. The prognostic implications of TROP2 are complex and show substantial variations across crucial clinicopathological subgroups, thus indicating that TROP2 is a suboptimal parameter to predict patient prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntigens, NeoplasmCell Adhesion MoleculesPhenotypeBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedPrognosisAdultAged, 80 and overNeoplasm StagingDisease-Free SurvivalImmunohistochemistry

Stichwörter der Autor:innen

TROP2colorectal carcinomaprognosis

Substanzen

TACSTD2 protein, humanAntigens, NeoplasmCell Adhesion MoleculesBiomarkers, Tumor

Autor:innen und Institutionen

  • Institute of Pathology, University Medical Center, Mainz, Germany.
  • Institute of Pathology, Philipps-University Marburg und University Hospital Marburg, Marburg, Germany.
  • Internal Medicine II, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Institute for Translational Cancer Research, German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
  • Department of Gastroenterology, Endocrinology and Infectious Diseases, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany.
  • Department of Surgery, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany.

ORCID-Profile: Markus Tschurtschenthaler, Katja Steiger, Moritz Jesinghaus

Förderung

  • Bundesministerium für Bildung und Forschung

Zitieren

APA

Foersch, S., Schmitt, M., Litmeyer, A. S., Tschurtschenthaler, M., Gress, T., Bartsch, D. K., Pfarr, N., Steiger, K., Denkert, C., & Jesinghaus, M. (2024). TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis. The Journal of Pathology: Clinical Research, 10(5). https://doi.org/10.1002/2056-4538.12394

Vancouver

Foersch S, Schmitt M, Litmeyer AS, Tschurtschenthaler M, Gress T, Bartsch DK, et al. TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis. The Journal of Pathology: Clinical Research. 2024;10(5). doi:10.1002/2056-4538.12394

BibTeX
@article{Foersch2024,
  author = {Foersch, Sebastian and Schmitt, Maxime and Litmeyer, Anne-Sophie and Tschurtschenthaler, Markus and Gress, Thomas and Bartsch, Detlef K and Pfarr, Nicole and Steiger, Katja and Denkert, Carsten and Jesinghaus, Moritz},
  title = {TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2024},
  volume = {10},
  number = {5},
  doi = {10.1002/2056-4538.12394}
}
Kostenlos starten →